Tempus AI vs Aidoc
A detailed comparison to help you choose between Tempus AI and Aidoc.
🏆
Verdict: Aidoc wins
Aidoc scores 4.2/5, edging out Tempus AI at 4.1/5. Hospital radiology departments and integrated health systems with meaningful acute imaging volumes that want one governed platform for many FDA-cleared triage algorithms instead of a stack of point solutions.
Tempus AI AI for precision medicine and clinical genomics | Aidoc AI powered radiology image analysis platform | |
|---|---|---|
| Rating | 4.1 (1 review) | 4.2 (1 review) |
| Pricing Model | paid | paid |
| Starting Price | From $1000/mo | From $10000/mo |
| Best For | Cancer centers, molecular labs and health systems building precision-oncology programs that need sequencing, interpretation and data products under one roof — and pharma partners buying real-world data access. | Hospital radiology departments and integrated health systems with meaningful acute imaging volumes that want one governed platform for many FDA-cleared triage algorithms instead of a stack of point solutions. |
| Free Tier | ||
| API Access | ||
| Team Features | ||
| Open Source | ||
| Tags | ssoteam features | api accessteam featuresgdpr compliant |
| Visit Tempus AI → | Visit Aidoc → |
Tempus AI
Pros
- + FY2025 revenue of $1.3B with 126% net revenue retention and >$1.1B remaining contract value — verifiable public-company financials, not marketing claims
- + Complete assay portfolio in one relationship: xT/xR comprehensive profiling, xF+ liquid biopsy, MRD monitoring, Ambry hereditary testing and OneOme pharmacogenomics (national launch July 2026)
- + Tempus One answered voice queries against the patient's own clinical and molecular profile in my testing, with report citations instead of generic text
- + Paige Predict extends the platform into digital pathology — 123 biomarkers predicted from standard H&E slides across 16 cancer types (vendor-published validation)
- + Trial matching is built into the report workflow, which is the practical bottleneck for oncology coordinators
Cons
- - No self-serve access, no trial, and no published pricing of any kind — the $1,000 entry figure floating around listings could not be verified
- - Oncology-first scope; primary care and non-oncology specialties have little reason to engage
- - Still net-loss-making (-$245.0M in 2025), and the portfolio is stitched from four recent acquisitions (Ambry, Paige, OneOme, Deep 6)
- - Model-performance and data-library claims are company-published; independent third-party validation is thinner than the press-release volume suggests
- - Enterprise sales motion means long procurement cycles for health systems
Aidoc
Pros
- + Widest FDA-cleared acute triage portfolio I have reviewed: 31 authorisations on the FDA's December 2025 list, plus the first multi-indication clearance covering 14 abdominal CT findings in one workflow
- + Multi-triage consolidation meaningfully reduces alert noise — one flagged study produces one stacked panel, not one pop-up per algorithm
- + Real-world deployment evidence: Mercy Health documented urgent case turnaround falling from 19.8h to 1.3h across 50+ hospitals, with 5,642 patients expedited from 50,749 flagged findings
- + Vendor-neutral aiOS layer lets a health system run third-party and Aidoc algorithms through one governance and notification stack (17 FDA-cleared algorithms deployed at Hartford HealthCare)
- + Care Coordination and Patient Management close the loop beyond triage: mobile alerts with image context, and report mining that routes incidental findings to facility-defined follow-up protocols
Cons
- - No public pricing, no trial, no free tier — third-party estimates of ~$50k/site/year baseline with $8k-$15k per extra module are unverifiable until you are deep in a sales process
- - Hospital-only: requires PACS/RIS/EHR integration work, so it is irrelevant to individual clinicians, small practices and low-volume facilities
- - 510(k) clearance for most modules does not itself require independent clinical performance data (per JAMA Network Open) — buyers should demand the study set, not just the clearance count
- - No public changelog for algorithm updates, which is a real gap for a system whose output feeds clinical decisions
- - Vendor performance figures (order-of-magnitude false-alert reduction, 1,600+ hospitals) are company claims I could not independently audit
Frequently Asked Questions
Which is better, Tempus AI or Aidoc?▼
Aidoc scores higher at 4.2/5 vs 4.1/5 for Tempus AI, making it the better-rated option in our comparison.
What is the difference between Tempus AI and Aidoc?▼
Tempus AI: Tempus AI runs clinical and genomic sequencing and builds the diagnostics and data products used in precision oncology and other specialties. Aidoc: Aidoc analyses medical imaging to flag urgent findings for radiologists and care teams, prioritising the cases that need attention first.
Is Tempus AI or Aidoc more affordable?▼
Tempus AI starts at €1000/mo, Aidoc starts at €10000/mo. Check the comparison table above for current pricing.
Stay in the loop
Get weekly updates on the best new AI tools, deals, and comparisons.
No spam. Unsubscribe anytime.